Brigatinib plus carboplatin–pemetrexed after lorlatinib failure in ALK-rearranged non-small cell lung cancer with co-occurring ALK I1171N and G1269A mutations: a case report

No standard targeted strategy exists after lorlatinib failure in ALK-rearranged non–small cell lung cancer (NSCLC). We report a 41-year-old man with metastatic ALK-rearranged lung adenocarcinoma who progressed sequentially on alectinib and lorlatinib. Re-biopsy with DNA/RNA next-generation sequencing (NGS) at lorlatinib progression revealed an EML4::ALK fusion with co-occurring ALK I1171N and G1269A mutations at high allele fractions, suggesting a cis configuration. Supported by in vitro data, he received brigatinib plus carboplatin–pemetrexed. After four cycles, the primary tumor regressed markedly, nodal disease showed a complete metabolic response, and intracranial findings remained stable. Grade 2 fatigue was the only adverse event; maintenance pemetrexed plus brigatinib is ongoing. Concurrent chemotherapy and short follow-up preclude attributing the response to brigatinib alone. This case highlights the value of repeat biopsy and NGS after lorlatinib failure and suggests that a brigatinib-containing chemotherapy regimen is feasible in this setting.

Authors

Institutions

Publication Details

Journal
Journal of Chemotherapy
Published
2026-11-16
DOI
https://doi.org/10.1080/1120009x.2026.2762664
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Brigatinib plus carboplatin–pemetrexed after lorlatinib failure in ALK-rearranged non-small cell lung cancer with co-occurring ALK I1171N and G1269A mutations: a case report

İbrahim Vedat Bayoğlu, Selver Işık, Osman Köstek, Ezgi Çoban et al.
Journal of Chemotherapy
Lung Cancer Treatments and Mutations
article

Brigatinib plus carboplatin–pemetrexed after lorlatinib failure in ALK-rearranged non-small cell lung cancer with co-occurring ALK I1171N and G1269A mutations: a case report

İbrahim Vedat Bayoğlu, Selver Işık, Osman Köstek, Ezgi Çoban, Ali Kaan Güren, Abdüssamet Çelebi, Nazım Can Demircan, Mustafa Alperen Tunç, Murat Sarı, Erkam Kocaaslan, Burak Paçacı, Fırat Akagündüz, Ahmet Demirel, Tugra Hakan Demir
article en

Abstract

No standard targeted strategy exists after lorlatinib failure in ALK-rearranged non–small cell lung cancer (NSCLC). We report a 41-year-old man with metastatic ALK-rearranged lung adenocarcinoma who progressed sequentially on alectinib and lorlatinib. Re-biopsy with DNA/RNA next-generation sequencing (NGS) at lorlatinib progression revealed an EML4::ALK fusion with co-occurring ALK I1171N and G1269A mutations at high allele fractions, suggesting a cis configuration. Supported by in vitro data, he received brigatinib plus carboplatin–pemetrexed. After four cycles, the primary tumor regressed markedly, nodal disease showed a complete metabolic response, and intracranial findings remained stable. Grade 2 fatigue was the only adverse event; maintenance pemetrexed plus brigatinib is ongoing. Concurrent chemotherapy and short follow-up preclude attributing the response to brigatinib alone. This case highlights the value of repeat biopsy and NGS after lorlatinib failure and suggests that a brigatinib-containing chemotherapy regimen is feasible in this setting.

Journal of Chemotherapy
Marmara University (TR)
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon